• Pfizer first-quarter 2026 earnings call drew CEO Albert Bourla, CFO David Denton, R&D chief Chris Boshoff, international commercial chief Alexandre de Germay, US commercial chief Aamir Malik, led by investor relations head Francesca DeMartino.
• Revenue came in at USD 14.5 billion, up 2% operationally, with adjusted diluted EPS USD 0.75; guidance reaffirmed for revenue USD 59.5 billion to USD 62.5 billion, adjusted diluted EPS USD 2.8 to USD 3.
• Vyndamax patent infringement settlements seen reshaping post-2028 outlook, with management projecting a five-year period of high single-digit revenue CAGR starting in 2029; Belgian court ruling on EU Comirnaty contracts cited as supportive for future EPS and cash flow.
• Management highlighted 22% operational growth in launched and acquired products to USD 3.1 billion, with Nurtec up 41% operationally; BD capacity put at about USD 7 billion, with large-scale M&A not a near-term priority.
• Metsera obesity program set for detailed ADA disclosures on VESPER-3, VESPER-1 extension, VESPER-2 weekly berobenatide; oncology catalysts flagged for midyear-to-2H readouts including SV lung cancer Phase 3 studies and MEVPRO-1 for mevrometostat.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.